See more : Suburban Minerals Corp. (SUBB) Income Statement Analysis – Financial Results
Complete financial analysis of Traws Pharma, Inc. (TRAW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Traws Pharma, Inc., a leading company in the industry within the sector.
You may be interested
- Teleste Corporation (TLT1V.HE) Income Statement Analysis – Financial Results
- Taiwan Fu Hsing Industrial Co.,Ltd. (9924.TW) Income Statement Analysis – Financial Results
- Nexans S.A. (NXPRF) Income Statement Analysis – Financial Results
- B-A-L Germany AG (DE000A2NBN90.SG) Income Statement Analysis – Financial Results
- Paramount Cosmetics (India) Limited (PARMCOS-B.BO) Income Statement Analysis – Financial Results
Traws Pharma, Inc. (TRAW)
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 226.00K | 226.00K | 226.00K | 231.00K | 2.18M | 1.23M | 787.00K | 5.55M | 11.46M | 800.00K | 4.75M | 46.19M | 1.49M |
| Cost of Revenue | 16.00K | 14.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 210.00K | 212.00K | 212.00K | 231.00K | 2.18M | 1.23M | 787.00K | 5.55M | 11.46M | 800.00K | 4.75M | 46.19M | 1.49M |
| Gross Profit Ratio | 92.92% | 93.81% | 93.81% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 11.41M | 11.41M | 7.30M | 16.90M | 15.52M | 16.87M | 19.03M | 20.07M | 25.90M | 49.43M | 50.18M | 52.76M | 22.62M |
| General & Administrative | 9.09M | 8.45M | 9.43M | 8.33M | 0.00 | 0.00 | 0.00 | 0.00 | 9.53M | 15.12M | 16.79M | 15.71M | 6.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.09M | 8.45M | 9.43M | 8.33M | 8.35M | 7.59M | 7.41M | 9.08M | 9.53M | 15.12M | 16.79M | 15.71M | 6.44M |
| Other Expenses | 0.00 | 663.00K | 12.00K | 48.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.51M | 19.85M | 16.72M | 25.22M | 23.87M | 24.46M | 26.44M | 29.15M | 35.43M | 64.54M | 66.98M | 68.47M | 29.06M |
| Cost & Expenses | 20.52M | 19.85M | 16.72M | 25.22M | 23.88M | 24.51M | 26.52M | 29.25M | 35.43M | 64.54M | 66.98M | 68.47M | 29.06M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 4.00K | 8.61M | 19.00K |
| Depreciation & Amortization | 16.00K | 14.00K | 14.00K | 13.00K | 14.00K | 55.00K | 88.00K | 96.00K | 150.00K | 434.00K | 446.00K | 319.00K | 316.00K |
| EBITDA | -20.28M | -19.61M | -16.48M | -24.98M | -21.69M | -23.23M | -25.65M | -23.61M | -23.82M | -63.31M | -61.67M | -20.99M | -25.96M |
| EBITDA Ratio | -8,974.34% | -8,678.32% | -7,434.96% | -10,723.81% | -993.36% | -1,891.45% | -3,259.09% | -425.66% | -207.94% | -7,913.75% | -1,297.45% | -45.43% | -1,745.73% |
| Operating Income | -20.30M | -19.63M | -16.50M | -24.99M | -21.70M | -23.28M | -25.74M | -23.70M | -23.97M | -63.74M | -62.22M | -22.28M | -27.57M |
| Operating Income Ratio | -8,981.42% | -8,684.51% | -7,299.12% | -10,819.48% | -994.00% | -1,895.93% | -3,270.27% | -427.39% | -209.25% | -7,968.00% | -1,309.11% | -48.23% | -1,854.27% |
| Total Other Income/Expenses | 1.35M | 663.00K | 333.00K | -160.00K | 206.00K | 2.75M | 1.66M | 4.05M | -35.00K | -32.00K | 101.00K | -7.63M | 1.28M |
| Income Before Tax | -18.95M | -18.96M | -16.16M | -25.15M | -21.49M | -20.53M | -24.08M | -19.65M | -24.01M | -63.78M | -62.12M | -29.91M | -26.29M |
| Income Before Tax Ratio | -8,384.07% | -8,391.15% | -7,151.77% | -10,888.74% | -984.56% | -1,672.15% | -3,059.59% | -354.36% | -209.56% | -7,972.00% | -1,306.99% | -64.76% | -1,768.26% |
| Income Tax Expense | 0.00 | -214.49K | -321.00K | 4.00K | 10.00K | -124.00K | 13.00K | 14.00K | 16.00K | 19.00K | 435.00K | 0.00 | 0.00 |
| Net Income | -18.95M | -18.96M | -16.16M | -25.16M | -21.50M | -20.57M | -24.09M | -19.67M | -23.98M | -63.68M | -62.54M | -29.91M | -26.29M |
| Net Income Ratio | -8,384.07% | -8,391.15% | -7,151.77% | -10,890.48% | -985.02% | -1,675.33% | -3,061.25% | -354.62% | -209.31% | -7,960.25% | -1,315.86% | -64.76% | -1,768.26% |
| EPS | -0.90 | -0.91 | -0.96 | -2.17 | -22.42 | -74.83 | -602.28 | -999.70 | -53.05K | -165.41K | -170.24K | -92.53K | -82.83K |
| EPS Diluted | -0.90 | -0.91 | -0.96 | -2.17 | -22.42 | -74.83 | -602.28 | -999.70 | -53.05K | -165.41K | -170.24K | -92.53K | -82.83K |
| Weighted Avg Shares Out | 20.99M | 20.91M | 16.83M | 11.60M | 958.97K | 274.94K | 40.00K | 19.67K | 452.00 | 385.00 | 381.00 | 366.00 | 366.00 |
| Weighted Avg Shares Out (Dil) | 20.99M | 20.91M | 16.83M | 11.60M | 958.97K | 274.94K | 40.00K | 19.67K | 452.00 | 385.00 | 381.00 | 366.00 | 366.00 |
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
NEWTOWN, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases, today outlined recent business updates and reported unaudited financial results for the...
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability results and plasma levels in the predicted therapeutic window, enabling selection of...
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws' Further Transformation and Growth
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws' shares expected to begin trading on a split-adjusted basis on September 23, 2024 NEWTOWN, Pa., Sept. 17, 2024 (GLOBE...
Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript
Traws Pharma, Inc. (NASDAQ:TRAW ) Corporate Update Call August 15, 2024 8:00 AM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Werner Cautreels - CEO Mark Guerin - CFO Conference Call Participants Chong Liu - Ladenburg Thalmann Operator Operator...
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put Traws on track to achieve key readouts for the clinical pipeline in...
Source: https://incomestatements.info
Category: Stock Reports